Poster Presentation 35th Lorne Cancer Conference 2023

Leveraging the nucleolar DNA damage response in ovarian cancer therapy (#233)

Ruofei Liu 1 , Diannita Kwang 1 , Dingyi Yu 1 , Kezia Gitareja 1 , Ching-seng Ang 2 , Clare Scott 3 , Rick Pearson 4 , Jian Kang 1 , Elaine Sanij 1
  1. St Vincent's Institute Medical Research, Fitzroy, VIC, Australia
  2. Melbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute,The University of Melbourne, Parkville, VIC, Australia
  3. The Walter and Eliza Hall Institute, Parkville, VIC, Australia
  4. Research Division, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia
Publish consent withheld
  1. Bywater, M. J. et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22, 51-65 (2012). https://doi.org:10.1016/j.ccr.2012.05.019
  2. Devlin, J. R. et al. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. Cancer Discov 6, 59-70 (2016). https://doi.org:10.1158/2159-8290.CD-14-0673
  3. Hein, N. et al. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood 129, 2882-2895 (2017). https://doi.org:10.1182/blood-2016-05-718171
  4. Lawrence, M. G. et al. CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Mol Cancer Ther 20, 2140-2150 (2021). https://doi.org:10.1158/1535-7163.MCT-20-0932
  5. Sanij, E. et al. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nat Commun 11, 2641 (2020). https://doi.org:10.1038/s41467-020-16393-4
  6. Hilton, J. et al. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. Nat Commun 13, 3607 (2022). https://doi.org:10.1038/s41467-022-31199-2
  7. Khot, A. et al. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discov 9, 1036-1049 (2019). https://doi.org:10.1158/2159-8290.CD-18-1455
  8. Yan, S. et al. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. British Journal of Cancer 124, 616-627 (2021). https://doi.org:10.1038/s41416-020-01158-z